307 related articles for article (PubMed ID: 18724297)
21. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Sperotto A; Damiani D; Zaja F; Patriarca F; Geromin A; Cerno M; Stocchi R; Tiribelli M; Skert C; Rinaldi C; Fanin R
Adv Clin Path; 2002 Apr; 6(2):77-85. PubMed ID: 19753729
[TBL] [Abstract][Full Text] [Related]
22. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
[TBL] [Abstract][Full Text] [Related]
24. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
25. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
[TBL] [Abstract][Full Text] [Related]
26. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
Vigouroux S; Milpied N; Andrieu JM; Colonna P; Ifrah N; Colombat P; Desablens B; Abgrall JF; Casassus P; Guilhot F; Briere J; Le Mevel A; Moreau P; Mechinaud F; Mahe B; Morineau N; Vigier M; Rapp MJ; Harousseau JL
Bone Marrow Transplant; 2002 May; 29(10):833-42. PubMed ID: 12058233
[TBL] [Abstract][Full Text] [Related]
27. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A
Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
[TBL] [Abstract][Full Text] [Related]
28. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
29. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
30. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
[TBL] [Abstract][Full Text] [Related]
31. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
32. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
33. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
34. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz JP; Munck JN; Divine M; Fermé C; Pény AM; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau JL
Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402
[TBL] [Abstract][Full Text] [Related]
35. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.
Czyz J; Szydlo R; Knopinska-Posluszny W; Hellmann A; Gozdzik J; Hansz J; Smolewski P; Robak T; Osowiecki M; Walewski J; Avigdor A; Nagler A; Zemelka T; Pawlicki M; Sawicki Z; Wojtukiewicz M; Kachel L; Holowiecki J; Charlinski G; Jedrzejczak WW
Bone Marrow Transplant; 2004 Jun; 33(12):1225-9. PubMed ID: 15094747
[TBL] [Abstract][Full Text] [Related]
36. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Lancet JE; Rapoport AP; Brasacchio R; Eberly S; Raubertas RF; Linder T; Muhs A; Duerst RE; Abboud CN; Packman CH; DiPersio JF; Constine LS; Rowe JM; Liesveld JL
Bone Marrow Transplant; 1998 Aug; 22(3):265-71. PubMed ID: 9720740
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
[TBL] [Abstract][Full Text] [Related]
38. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
[TBL] [Abstract][Full Text] [Related]
39. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Morabito F; Stelitano C; Luminari S; Mammi C; Marcheselli L; Callea V; Gentile M; Polimeno G; Merli F; Molica S; Gobbi P; Angrilli F; Brugiatelli M; Federico M
Bone Marrow Transplant; 2006 Feb; 37(3):283-8. PubMed ID: 16327815
[TBL] [Abstract][Full Text] [Related]
40. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
